BACKGROUND: Thyrotoxic periodic paralysis (TPP), familial periodic paralysis (FPP), and sporadic periodic paralysis (SPP) are common causes of hypokalemic periodic paralysis and have similar clinical presentations, thus possibly sharing the identical mutations. METHODS: We analyzed the role of the three known CACNA1S gene mutations (R528H, R1239H, and R1239G) in Chinese patients, including two FPP families, 36 TPP patients, 12 SPP patients, and their relatives. Fifty unrelated healthy subjects were also studied. Genomic DNA was prepared from the peripheral blood of all patients, their family members, and healthy subjects. Mutations of the CACNA1S gene were screened using polymerase chain reaction-based restriction analysis. RESULTS: Two FPP families had the R528H point mutation, but with incomplete penetrance occurring more commonly in men than in women. Only one SPP patient had a de novo mutation (R528H). None of the TPP patients had mutations in the three hot spots. CONCLUSION: Patients with FPP have R528H mutations in the CACNA1S gene. Only a few patients with SPP may share similar mutations with FPP. TPP patients do not carry any of the three known gene mutations.
BACKGROUND:Thyrotoxic periodic paralysis (TPP), familial periodic paralysis (FPP), and sporadic periodic paralysis (SPP) are common causes of hypokalemic periodic paralysis and have similar clinical presentations, thus possibly sharing the identical mutations. METHODS: We analyzed the role of the three known CACNA1S gene mutations (R528H, R1239H, and R1239G) in Chinese patients, including two FPP families, 36 TPPpatients, 12 SPP patients, and their relatives. Fifty unrelated healthy subjects were also studied. Genomic DNA was prepared from the peripheral blood of all patients, their family members, and healthy subjects. Mutations of the CACNA1S gene were screened using polymerase chain reaction-based restriction analysis. RESULTS: Two FPP families had the R528H point mutation, but with incomplete penetrance occurring more commonly in men than in women. Only one SPP patient had a de novo mutation (R528H). None of the TPPpatients had mutations in the three hot spots. CONCLUSION:Patients with FPP have R528H mutations in the CACNA1S gene. Only a few patients with SPP may share similar mutations with FPP. TPPpatients do not carry any of the three known gene mutations.
Authors: K Kageyama; K Terui; S Tsutaya; E Matsuda; M Shoji; S Sakihara; T Nigawara; S Takayasu; T Moriyama; M Yasujima; T Suda Journal: J Endocrinol Invest Date: 2006-11 Impact factor: 4.256
Authors: Frank Geller; Bjarke Feenstra; Hao Zhang; John R Shaffer; Thomas Hansen; Ann-Louise Esserlind; Heather A Boyd; Ellen A Nohr; Nicholas J Timpson; Ghazaleh Fatemifar; Lavinia Paternoster; David M Evans; Robert J Weyant; Steven M Levy; Mark Lathrop; George Davey Smith; Jeffrey C Murray; Jes Olesen; Thomas Werge; Mary L Marazita; Thorkild I A Sørensen; Mads Melbye Journal: PLoS Genet Date: 2011-09-08 Impact factor: 5.917
Authors: Katrin Sangkuhl; Robert T Dirksen; Maria L Alvarellos; Russ B Altman; Teri E Klein Journal: Pharmacogenet Genomics Date: 2020-02 Impact factor: 2.000
Authors: Marlyn Zapata; Ilda S Kunii; Rolf M Paninka; Denise M N Simões; Víctor A Castillo; Archivaldo Reche; Rui M B Maciel; Magnus R Dias da Silva Journal: Biol Open Date: 2014-07-25 Impact factor: 2.422
Authors: Danielle Carpenter; Christopher Ringrose; Vincenzo Leo; Andrew Morris; Rachel L Robinson; P Jane Halsall; Philip M Hopkins; Marie-Anne Shaw Journal: BMC Med Genet Date: 2009-10-13 Impact factor: 2.103